The therapeutic efficacy of umbilical cord mesenchymal stem cells (UCMSCs) in acute respiratory distress syndrome (ARDS) is mainly limited by the efficiency of homing of UCMSCs toward tissue damage. C-X-C chemokine receptor type 7 (CXCR7), which is involved in the mobilization of UCMSCs, is only expressed on the surface of a small proportion of UCMSCs. This study examined whether overexpression of CXCR7 in UCMSCs (UCMSCsOE-CXCR7) could improve their homing efficiency, and therefore, improve their effectiveness in fibrosis repair at the site of lung injury caused by ARDS. A lentiviral vector expressing CXCR7 was built and then transfect into UCMSCs. The impacts of CXCR7 expression of the proliferationand homing of UCMSCs were examined in a lipopolysaccharide-induced ARDS mouse model. The potential role and underlying mechanism of CXCR7 were examined by performing scratch assays, transwell assays, and immunoassays. The therapeutic dose and treatment time of UCMSCsOE-CXCR7 were directly proportional to their therapeutic effect on lung injury. In addition, overexpression of CXCR7 increased SDF-1-induced proliferation and migration of lung epithelial cells (Base-2b cells), and upregulation of CXCR7 inhibited α-SMA expression, suggesting that CXCR7 may have a role in alleviating pulmonary fibrosis caused by ARDS. Overexpression of CXCR7 in UCMSCs may improve their therapeutic effect of acute lung injury mouse, The mechanism of fibrosis repair by CXCR7 is inhibition of Jag1 via suppression of the Wnt/β-catenin pathway under the chemotaxis of SDF-1.
20 November 2023 in International Immunopharmacology
This study aimed to investigate the therapeutic potential of dasatinib, an FDA-approved drug for chronic myeloid leukemia, in sepsis-induced acute lung injury (ALI). In the in vitro part of the study, RAW 264.7 macrophages were stimulated with lipopolysaccharide (LPS), and the anti-inflammatory effects of dasatinib were assessed by measuring pro-inflammatory mediators and cytokines. In the in vivo part, ALI was induced in mice through intraperitoneal LPS injection. The researchers investigated alveolar-capillary permeability, the inflammatory response, and the therapeutic efficacy of dasatinib in ALI. Dasatinib administration was found to attenuate inflammation by inhibiting the mTOR pathway. In the in vivo experiments, dasatinib reduced the levels of pro-inflammatory cytokines and chemokines in bronchoalveolar lavage fluid (BALF). It also decreased lung tissue permeability, as evidenced by a lower amount of Evans blue dye detected after ALI. Furthermore, dasatinib alleviated lung histological damage and reduced the lung injury grade, demonstrating its protective role in ALI. By inhibiting the mTOR pathway in macrophages, dasatinib exhibited a protective and anti-inflammatory effect on ALI. It reduced the intrapulmonary inflammatory response, prevented capillary disruption, and inhibited the accumulation of inflammatory cells. These findings suggest that dasatinib holds promise as a potential treatment option for protecting lung tissue in ALI.